Biocytogen

🌟 Join Us for an Insightful Webinar on HLA-Humanized Mice in Preclinical Research! Curious about how HLA genes play a role in immune response and impact drug development? Discover the potential of Biocytogen’s HLA-humanized mice models to transform preclinical testing! 🧬 📅 Date & Time: Wed, Nov 20, 1:00 PM EST 🎙️ Speaker: Dr. Leila Kokabee, Associate Director, In Vitro/Ex Vivo/Flow Cytometry Platform Leader at Biocytogen 👉 Register now: https://lnkd.in/ezAbWS_p 🎯 What you’ll learn: - The role of HLA genes in immune response and their significance in preclinical research. - How Biocytogen’s HLA-humanized mice incorporate human HLA genes for more precise testing of drug efficacy and safety. - Diverse applications of HLA-humanized mice in fields such as immunotherapy, vaccine research, autoimmune disease modeling, and more. #Webinar #HLAHumanizedMice #DrugDevelopment #PreclinicalResearch #Immunotherapy #Biocytogen #PharmaceuticalResearch #HLA #MouseModel

Expand RA Therapy Options with Biocytogen’s Antibodies🔬💪 Rheumatoid arthritis (RA) affects millions, causing painful joint damage and, in severe cases, disability. With cases expected to reach 45 million by 2030, the demand for innovative RA therapies is growing. Biocytogen’s RenMice® antibody discovery platform offers high-affinity, high-specificity RA-related antibodies to support the development of advanced treatment options, such as CD40 monoclonal antibodies (YH015) and CXCL13 monoclonal antibodies. Contact us today to explore evaluation, licensing, or co-development opportunities! #Biocytogen #RheumatoidArthritis #RAtherapy #AntibodyInnovation #Biotech

Meet Us at World ADC San Diego 2024! 🌐🔬 We’re thrilled to join World ADC San Diego 2024, the largest global conference focused on antibody-drug conjugates! From November 4-7, top innovators and experts will gather in San Diego to share insights and drive advancements in ADCs. Join us as we showcase our latest progress in oncology care. Let’s connect, collaborate, and push the boundaries of science together! 🚀 #Biocytogen #WorldADC2024 #ADCTherapy #Oncology #Innovation #Biotech

Biocytogen’s Ophthalmology Models and Services: Advancing Eye Disease Drug Development 👁️💊 As eye diseases like AMD, glaucoma, dry eye disease (DED), and myopia rise due to factors like allergens, aging, and unhealthy lifestyle habits, the demand for ophthalmic drugs is increasing globally. Biocytogen supports this growing need with advanced drug-targeted humanized mouse models and specialized pathology services for ophthalmic research. Our models provide researchers with the tools to effectively target a range of eye diseases within a human genetic context, streamlining the path to innovative therapies. #Biocytogen #Ophthalmology #DrugDevelopment #EyeHealth #Biotech #Innovation

Thank You for Making Gene-ius Break Swing & Sip a Success! ⛳🍸 A heartfelt thank you to everyone who joined us at Gene-ius Break Swing & Sip! Your energy made the event a true success, from insightful conversations to shared excitement about the latest advancements in biotech. It was inspiring to connect with so many passionate professionals committed to innovation in the field. We can’t wait for more chances to connect and collaborate! Stay tuned for future events—we look forward to seeing you! #GeneiusBreak #SwingAndSip #TopGolf #Biocytogen #BiotechNetworking #Innovation #DrugDiscovery

🌟 Meet Us at the #SITC 2024! 🌟 We’re thrilled to attend the Society for Immunotherapy of Cancer (SITC) 2024! Meet us at booth #319 from November 6th to 10th in Houston, we’ll join top experts and visionaries to exchange ideas, gain insights, and propel cancer treatment forward. Let’s connect and explore the future of immunotherapy together! 🗓️Date: Nov. 6th - 10th CST  📍Location: Booth #319, George R. Brown Convention Center in Houston, TX #SITC2024 #Immunotherapy #Biocytogen #CancerResearch #Innovation #Biotech 

Behind the Scenes with Kareem: A Journey of Growth and Dedication at Biocytogen 🚀 Meet Kareem, a key member of Biocytogen’s pharmacology team, brings passion and an adventurous spirit to his work. From a fresh graduate to taking care of large-scale PK studies, his journey is one of perseverance and learning. Outside the lab, Kareem recharges through hiking, kickboxing, and is excited to adopt a dog soon! His proactive approach ensures smooth experiments and well-cared-for subjects, making him a standout. At Biocytogen, Kareem has sharpened his skills, valuing teamwork and attention to detail. His advice? Stay focused, learn fast, and embrace challenges. Passion and drive know no limits! Read more about Kareem: https://lnkd.in/ey5q6Y26

🎉Fun Fact with Biocytogen, let's see who’s got the sharpest guess!  #LinkedInPoll #HumanizedModels #BiologyTrivia #ResearchInsights

🎉 We Made  It! Thank You for Making Gene-ius Break Maryland a Success! 🚀 A huge thank you to all the incredible speakers, panelists, and attendees who helped make Biocytogen's Gene-ius Break Maryland Forum a hit! Your enthusiasm truly energized the event. It was fantastic connecting with so many talented professionals and sharing insights into our latest biotech breakthroughs. We’re excited about the future of collaboration and innovation. Stay tuned for more opportunities to connect and explore cutting-edge developments. Looking forward to seeing you at our future event! #Biocytogen #GeneiusBreak #BiotechNetworking #Maryland #Innovation #Collaboration

Biocytogen’s CCR5 Antibody Assets: Advancing Therapies for NASH 🧬 Non-Alcoholic Steatohepatitis (NASH) is a serious liver disease characterized by fat buildup, inflammation, and fibrosis. CCR5 plays a key role in the pathogenesis of NASH by promoting the recruitment of immune cells to the liver, contributing to chronic inflammation and fibrosis. Blocking CCR5 has emerged as a promising therapeutic strategy, with Cenicriviroc showing significant potential in clinical trials to improve liver fibrosis. At Biocytogen, we’re leveraging our proprietary RenMice platform to develop fully human antibodies targeting CCR5, opening new possibilities for NASH treatment. We invite potential partners to collaborate with us in pioneering innovative therapies to combat NASH and liver fibrosis! #NASH #LiverDisease #CCR5 #Biocytogen #RenMice #FibrosisResearch #BiotechInnovation #Healthcare